{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T04:41:27Z","timestamp":1789965687546,"version":"4.0.1"},"reference-count":82,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,1,31]],"date-time":"2022-01-31T00:00:00Z","timestamp":1643587200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,31]],"date-time":"2022-01-31T00:00:00Z","timestamp":1643587200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Pediatr"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s00431-021-04357-9","type":"journal-article","created":{"date-parts":[[2022,1,30]],"date-time":"2022-01-30T19:04:06Z","timestamp":1643569446000},"page":"1395-1404","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["The immunopathogenesis of idiopathic nephrotic syndrome: a narrative review of the literature"],"prefix":"10.1007","volume":"181","author":[{"given":"Konstantina","family":"Kitsou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varvara","family":"Askiti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andromachi","family":"Mitsioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vana","family":"Spoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,31]]},"reference":[{"key":"4357_CR1","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S0140-6736(18)30536-1","volume":"392","author":"DG Noone","year":"2018","unstructured":"Noone DG, Iijima K, Parekh R (2018) Idiopathic nephrotic syndrome in children. Lancet 392:61\u201374. https:\/\/doi.org\/10.1016\/S0140-6736(18)30536-1","journal-title":"Lancet"},{"key":"4357_CR2","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s00467-015-3116-4","volume":"31","author":"J M\u00fcller-Deile","year":"2016","unstructured":"M\u00fcller-Deile J, Schiffer M (2016) Podocyte directed therapy of nephrotic syndrome\u2014can we bring the inside out? Pediatr Nephrol 31:393\u2013405. https:\/\/doi.org\/10.1007\/s00467-015-3116-4","journal-title":"Pediatr Nephrol"},{"key":"4357_CR3","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S0140-6736(03)14184-0","volume":"362","author":"AA Eddy","year":"2003","unstructured":"Eddy AA, Symons JM (2003) Nephrotic syndrome in childhood. Lancet (London, England) 362:629\u2013639. https:\/\/doi.org\/10.1016\/S0140-6736(03)14184-0","journal-title":"Lancet (London, England)"},{"key":"4357_CR4","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.1007\/s00467-016-3509-z","volume":"31","author":"C Dossier","year":"2016","unstructured":"Dossier C, Lapidus N, Bayer F et al (2016) Epidemiology of idiopathic nephrotic syndrome in children: endemic or epidemic? Pediatr Nephrol 31:2299\u20132308. https:\/\/doi.org\/10.1007\/s00467-016-3509-z","journal-title":"Pediatr Nephrol"},{"key":"4357_CR5","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/s0140-6736(74)91880-7","volume":"2","author":"RJ Shalhoub","year":"1974","unstructured":"Shalhoub RJ (1974) Pathogenesis of lipoid nephrosis: a disorder of T-cell function. Lancet (London, England) 2:556\u2013560. https:\/\/doi.org\/10.1016\/s0140-6736(74)91880-7","journal-title":"Lancet (London, England)"},{"key":"4357_CR6","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1053\/j.ackd.2015.06.003","volume":"22","author":"A Gupta","year":"2015","unstructured":"Gupta A, Quigg RJ (2015) Glomerular diseases associated with hepatitis B and C. Adv Chronic Kidney Dis 22:343\u2013351. https:\/\/doi.org\/10.1053\/j.ackd.2015.06.003","journal-title":"Adv Chronic Kidney Dis"},{"key":"4357_CR7","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1007\/s00467-014-2860-1","volume":"29","author":"C Dossier","year":"2014","unstructured":"Dossier C, Sellier-Leclerc A-L, Rousseau A et al (2014) Prevalence of herpesviruses at onset of idiopathic nephrotic syndrome. Pediatr Nephrol 29:2325\u20132331. https:\/\/doi.org\/10.1007\/s00467-014-2860-1","journal-title":"Pediatr Nephrol"},{"key":"4357_CR8","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.1007\/s00467-014-2835-2","volume":"29","author":"C-C Wei","year":"2014","unstructured":"Wei C-C, Tsai J-D, Lin C-L et al (2014) Increased risk of idiopathic nephrotic syndrome in children with atopic dermatitis. Pediatr Nephrol 29:2157\u20132163. https:\/\/doi.org\/10.1007\/s00467-014-2835-2","journal-title":"Pediatr Nephrol"},{"key":"4357_CR9","doi-asserted-by":"publisher","first-page":"370","DOI":"10.2188\/JEA.JE20140167","volume":"25","author":"C-C Wei","year":"2015","unstructured":"Wei C-C, Lin C-L, Shen T-C, Sung F-C (2015) Occurrence of common allergic diseases in children with idiopathic nephrotic syndrome. J Epidemiol 25:370. https:\/\/doi.org\/10.2188\/JEA.JE20140167","journal-title":"J Epidemiol"},{"key":"4357_CR10","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1681\/ASN.2017111185","volume":"29","author":"H Debiec","year":"2018","unstructured":"Debiec H, Dossier C, Letouz\u00e9 E et al (2018) Transethnic, genome-wide analysis reveals immune-related risk alleles and phenotypic correlates in pediatric steroid-sensitive nephrotic syndrome. J Am Soc Nephrol 29:2000\u20132013. https:\/\/doi.org\/10.1681\/ASN.2017111185","journal-title":"J Am Soc Nephrol"},{"key":"4357_CR11","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/s00431-016-2694-x","volume":"175","author":"HE Baris","year":"2016","unstructured":"Baris HE, Baris S, Karakoc-Aydiner E et al (2016) The effect of systemic corticosteroids on the innate and adaptive immune system in children with steroid responsive nephrotic syndrome. Eur J Pediatr 175:685\u2013693. https:\/\/doi.org\/10.1007\/s00431-016-2694-x","journal-title":"Eur J Pediatr"},{"key":"4357_CR12","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1038\/s41390-018-0088-7","volume":"84","author":"D Bhatia","year":"2018","unstructured":"Bhatia D, Sinha A, Hari P et al (2018) Rituximab modulates T- and B-lymphocyte subsets and urinary CD80 excretion in patients with steroid-dependent nephrotic syndrome. Pediatr Res 84:520\u2013526. https:\/\/doi.org\/10.1038\/s41390-018-0088-7","journal-title":"Pediatr Res"},{"key":"4357_CR13","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.clim.2011.02.018","volume":"139","author":"L Liu","year":"2011","unstructured":"Liu L, Qin Y, Cai J et al (2011) Th17\/Treg imbalance in adult patients with minimal change nephrotic syndrome. Clin Immunol 139:314\u2013320. https:\/\/doi.org\/10.1016\/j.clim.2011.02.018","journal-title":"Clin Immunol"},{"key":"4357_CR14","doi-asserted-by":"publisher","unstructured":"Chung CF, Kitzler T, Kachurina N et al (2019) Intrinsic tumor necrosis factor-\u03b1 pathway is activated in a subset of patients with focal segmental glomerulosclerosis. PLoS ONE 14.\u00a0https:\/\/doi.org\/10.1371\/journal.pone.0216426","DOI":"10.1371\/journal.pone.0216426"},{"key":"4357_CR15","doi-asserted-by":"publisher","unstructured":"Otalora L, Chavez E, Watford D et al (2019) Identification of glomerular and podocyte-specific genes and pathways activated by sera of patients with focal segmental glomerulosclerosis. PLoS ONE 14.\u00a0https:\/\/doi.org\/10.1371\/journal.pone.0222948","DOI":"10.1371\/journal.pone.0222948"},{"key":"4357_CR16","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.cyto.2017.06.021","volume":"102","author":"DM Youssef","year":"2018","unstructured":"Youssef DM, El-Shal AS, Hussein S et al (2018) Tumor necrosis factor alpha gene polymorphisms and haplotypes in Egyptian children with nephrotic syndrome. Cytokine 102:76\u201382. https:\/\/doi.org\/10.1016\/j.cyto.2017.06.021","journal-title":"Cytokine"},{"key":"4357_CR17","first-page":"30","volume":"19","author":"A Weissbach","year":"2017","unstructured":"Weissbach A, Garty BZ, Lagovsky I et al (2017) Serum tumor necrosis factor-alpha levels in children with nephrotic syndrome: a pilot study. Isr Med Assoc J 19:30\u201333","journal-title":"Isr Med Assoc J"},{"key":"4357_CR18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0157907","volume":"11","author":"AH Zea","year":"2016","unstructured":"Zea AH, Stewart T, Ascani J et al (2016) Activation of the IL-2 receptor in podocytes: a potential mechanism for podocyte injury in idiopathic nephrotic syndrome? PLoS ONE 11:e0157907. https:\/\/doi.org\/10.1371\/journal.pone.0157907","journal-title":"PLoS ONE"},{"key":"4357_CR19","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1007\/s00467-004-1569-y","volume":"19","author":"H Shimoyama","year":"2004","unstructured":"Shimoyama H, Nakajima M, Naka H et al (2004) Up-regulation of interleukin-2 mRNA in children with idiopathic nephrotic syndrome. Pediatr Nephrol 19:1115\u20131121. https:\/\/doi.org\/10.1007\/s00467-004-1569-y","journal-title":"Pediatr Nephrol"},{"key":"4357_CR20","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.cyto.2015.08.002","volume":"76","author":"D Kalavrizioti","year":"2015","unstructured":"Kalavrizioti D, Gerolymos M, Rodi M et al (2015) T helper (Th)-cytokines in the urine of patients with primary glomerulonephritis treated with immunosuppressive drugs: Can they predict outcome? Cytokine 76:260\u2013269. https:\/\/doi.org\/10.1016\/j.cyto.2015.08.002","journal-title":"Cytokine"},{"key":"4357_CR21","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.cyto.2008.08.012","volume":"44","author":"N Printza","year":"2008","unstructured":"Printza N, Papachristou F, Tzimouli V et al (2008) IL-18 is correlated with type-2 immune response in children with steroid sensitive nephrotic syndrome. Cytokine 44:262\u2013268. https:\/\/doi.org\/10.1016\/j.cyto.2008.08.012","journal-title":"Cytokine"},{"key":"4357_CR22","doi-asserted-by":"publisher","unstructured":"Stangou M, Spartalis \u039c, Daikidou D-V et al (2016) Impact of \u03a4h1 and \u03a4h2 cytokines in the progression of idiopathic nephrotic syndrome due to focal segmental glomerulosclerosis and minimal change disease. J Nephropathol 6:187\u2013195. https:\/\/doi.org\/10.15171\/jnp.2017.32","DOI":"10.15171\/jnp.2017.32"},{"key":"4357_CR23","doi-asserted-by":"publisher","first-page":"4426","DOI":"10.3892\/etm.2018.5923","volume":"15","author":"J Zhou","year":"2018","unstructured":"Zhou J, Shi F, Xun W (2018) Leptin, hs-CRP, IL-18 and urinary protein before and after treatment of children with nephrotic syndrome. Exp Ther Med 15:4426\u20134430. https:\/\/doi.org\/10.3892\/etm.2018.5923","journal-title":"Exp Ther Med"},{"key":"4357_CR24","doi-asserted-by":"publisher","unstructured":"Kim AH, Chung J-J, Akilesh S et al (2017) B cell-derived IL-4 acts on podocytes to induce proteinuria and foot process effacement. JCI insight 2.\u00a0https:\/\/doi.org\/10.1172\/jci.insight.81836","DOI":"10.1172\/jci.insight.81836"},{"key":"4357_CR25","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s00467-008-1003-y","volume":"24","author":"Y Ikeuchi","year":"2009","unstructured":"Ikeuchi Y, Kobayashi Y, Arakawa H et al (2009) Polymorphisms in interleukin-4-related genes in patients with minimal change nephrotic syndrome. Pediatr Nephrol 24:489\u2013495. https:\/\/doi.org\/10.1007\/s00467-008-1003-y","journal-title":"Pediatr Nephrol"},{"key":"4357_CR26","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1007\/s00011-017-1058-y","volume":"66","author":"T-S Ha","year":"2017","unstructured":"Ha T-S, Nam JA, Seong S-B et al (2017) Montelukast improves the changes of cytoskeletal and adaptor proteins of human podocytes by interleukin-13. Inflamm Res 66:793\u2013802. https:\/\/doi.org\/10.1007\/s00011-017-1058-y","journal-title":"Inflamm Res"},{"key":"4357_CR27","doi-asserted-by":"publisher","first-page":"426","DOI":"10.3349\/ymj.2015.56.2.426","volume":"56","author":"SJ Park","year":"2015","unstructured":"Park SJ, Saleem MA, Nam J-A et al (2015) Effects of interleukin-13 and montelukast on the expression of zonula occludens-1 in human podocytes. Yonsei Med J 56:426\u2013432. https:\/\/doi.org\/10.3349\/ymj.2015.56.2.426","journal-title":"Yonsei Med J"},{"key":"4357_CR28","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1038\/s41390-020-1022-3","volume":"89","author":"S Tsuji","year":"2021","unstructured":"Tsuji S, Akagawa S, Akagawa Y et al (2021) Idiopathic nephrotic syndrome in children: role of regulatory T cells and gut microbiota. Pediatr Res 89:1185\u20131191. https:\/\/doi.org\/10.1038\/s41390-020-1022-3","journal-title":"Pediatr Res"},{"key":"4357_CR29","doi-asserted-by":"publisher","first-page":"114","DOI":"10.3389\/fped.2019.00114","volume":"7","author":"FTL Guimar\u00e3es","year":"2019","unstructured":"Guimar\u00e3es FTL, Ferreira RN, Brito-Melo GEA et al (2019) Pediatric patients with steroid-sensitive nephrotic syndrome have higher expression of T regulatory lymphocytes in comparison to steroid-resistant disease. Front Pediatr 7:114. https:\/\/doi.org\/10.3389\/fped.2019.00114","journal-title":"Front Pediatr"},{"key":"4357_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.trsl.2021.03.019","author":"C-Y Chan","year":"2021","unstructured":"Chan C-Y, Teo S, Lu L et al (2021) Low regulatory T-cells: a distinct immunological subgroup in minimal change nephrotic syndrome with early relapse following rituximab therapy. Transl Res. https:\/\/doi.org\/10.1016\/j.trsl.2021.03.019","journal-title":"Transl Res"},{"key":"4357_CR31","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1159\/000350161","volume":"37","author":"L Wang","year":"2013","unstructured":"Wang L, Li Q, Wang L et al (2013) The role of Th17\/IL-17 in the pathogenesis of primary nephrotic syndrome in children. Kidney Blood Press Res 37:332\u2013345. https:\/\/doi.org\/10.1159\/000350161","journal-title":"Kidney Blood Press Res"},{"key":"4357_CR32","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1007\/s00467-009-1194-x","volume":"24","author":"XS Shao","year":"2009","unstructured":"Shao XS, Yang XQ, Zhao XD et al (2009) The prevalence of Th17 cells and FOXP3 regulate T cells (Treg) in children with primary nephrotic syndrome. Pediatr Nephrol 24:1683\u20131690. https:\/\/doi.org\/10.1007\/s00467-009-1194-x","journal-title":"Pediatr Nephrol"},{"key":"4357_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/JIR.S124947","volume":"10","author":"A Al-Eisa","year":"2017","unstructured":"Al-Eisa A, Al Rushood M, Al-Attiyah R (2017) Urinary excretion of IL-1\u03b2, IL-6 and IL-8 cytokines during relapse and remission of idiopathic nephrotic syndrome. J Inflamm Res 10:1\u20135. https:\/\/doi.org\/10.2147\/JIR.S124947","journal-title":"J Inflamm Res"},{"key":"4357_CR34","doi-asserted-by":"publisher","first-page":"F913","DOI":"10.1152\/ajprenal.00093.2019","volume":"317","author":"CJ May","year":"2019","unstructured":"May CJ, Welsh GI, Chesor M et al (2019) Human Th17 cells produce a soluble mediator that increases podocyte motility via signaling pathways that mimic PAR-1 activation. Am J Physiol Renal Physiol 317:F913\u2013F921. https:\/\/doi.org\/10.1152\/ajprenal.00093.2019","journal-title":"Am J Physiol Renal Physiol"},{"key":"4357_CR35","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1681\/ASN.2012020133","volume":"24","author":"A Goldwich","year":"2013","unstructured":"Goldwich A, Burkard M, Olke M et al (2013) Podocytes are nonhematopoietic professional antigen-presenting cells. J Am Soc Nephrol 24:906\u2013916. https:\/\/doi.org\/10.1681\/ASN.2012020133","journal-title":"J Am Soc Nephrol"},{"key":"4357_CR36","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1172\/JCI20402","volume":"113","author":"J Reiser","year":"2004","unstructured":"Reiser J, von Gersdorff G, Loos M et al (2004) Induction of B7\u20131 in podocytes is associated with nephrotic syndrome. J Clin Invest 113:1390\u20131397. https:\/\/doi.org\/10.1172\/JCI20402","journal-title":"J Clin Invest"},{"key":"4357_CR37","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1681\/ASN.2007080836","volume":"20","author":"EH Garin","year":"2009","unstructured":"Garin EH, Diaz LN, Mu W et al (2009) Urinary CD80 excretion increases in idiopathic minimal-change disease. J Am Soc Nephrol 20:260\u2013266. https:\/\/doi.org\/10.1681\/ASN.2007080836","journal-title":"J Am Soc Nephrol"},{"key":"4357_CR38","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1007\/s00467-013-2498-4","volume":"28","author":"T Ishimoto","year":"2013","unstructured":"Ishimoto T, Cara-Fuentes G, Wang H et al (2013) Serum from minimal change patients in relapse increases CD80 expression in cultured podocytes. Pediatr Nephrol 28:1803\u20131812. https:\/\/doi.org\/10.1007\/s00467-013-2498-4","journal-title":"Pediatr Nephrol"},{"key":"4357_CR39","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1038\/ki.2010.143","volume":"78","author":"EH Garin","year":"2010","unstructured":"Garin EH, Mu W, Arthur JM et al (2010) Urinary CD80 is elevated in minimal change disease but not in focal segmental glomerulosclerosis. Kidney Int 78:296\u2013302. https:\/\/doi.org\/10.1038\/ki.2010.143","journal-title":"Kidney Int"},{"key":"4357_CR40","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s00467-014-2915-3","volume":"30","author":"C Ling","year":"2015","unstructured":"Ling C, Liu X, Shen Y et al (2015) Urinary CD80 levels as a diagnostic biomarker of minimal change disease. Pediatr Nephrol 30:309\u2013316. https:\/\/doi.org\/10.1007\/s00467-014-2915-3","journal-title":"Pediatr Nephrol"},{"key":"4357_CR41","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1007\/s00467-018-3885-7","volume":"33","author":"C Ling","year":"2018","unstructured":"Ling C, Liu X, Shen Y et al (2018) Urinary CD80 excretion is a predictor of good outcome in children with primary nephrotic syndrome. Pediatr Nephrol 33:1183\u20131187. https:\/\/doi.org\/10.1007\/s00467-018-3885-7","journal-title":"Pediatr Nephrol"},{"key":"4357_CR42","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1111\/ped.14005","volume":"61","author":"FK Eroglu","year":"2019","unstructured":"Eroglu FK, Orhan D, \u0130n\u00f6z\u00fc M et al (2019) CD80 expression and infiltrating regulatory T cells in idiopathic nephrotic syndrome of childhood. Pediatr Int 61:1250\u20131256. https:\/\/doi.org\/10.1111\/ped.14005","journal-title":"Pediatr Int"},{"key":"4357_CR43","doi-asserted-by":"publisher","first-page":"2732","DOI":"10.1681\/ASN.2006121346","volume":"18","author":"A-L Sellier-Leclerc","year":"2007","unstructured":"Sellier-Leclerc A-L, Duval A, Riveron S et al (2007) A humanized mouse model of idiopathic nephrotic syndrome suggests a pathogenic role for immature cells. J Am Soc Nephrol 18:2732\u20132739. https:\/\/doi.org\/10.1681\/ASN.2006121346","journal-title":"J Am Soc Nephrol"},{"key":"4357_CR44","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1007\/s00467-008-0793-2","volume":"23","author":"H Lapillonne","year":"2008","unstructured":"Lapillonne H, Leclerc A, Ulinski T et al (2008) Stem cell mobilization in idiopathic steroid-sensitive nephrotic syndrome. Pediatr Nephrol 23:1251\u20131256. https:\/\/doi.org\/10.1007\/s00467-008-0793-2","journal-title":"Pediatr Nephrol"},{"key":"4357_CR45","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1093\/ndt\/gfm683","volume":"23","author":"MS Ahmed","year":"2007","unstructured":"Ahmed MS, Wong CF (2007) Rituximab and nephrotic syndrome: a new therapeutic hope? Nephrol Dial Transplant 23:11\u201317. https:\/\/doi.org\/10.1093\/ndt\/gfm683","journal-title":"Nephrol Dial Transplant"},{"key":"4357_CR46","doi-asserted-by":"publisher","first-page":"178","DOI":"10.3389\/fped.2019.00178","volume":"7","author":"M Kallash","year":"2019","unstructured":"Kallash M, Smoyer WE, Mahan JD (2019) Rituximab use in the management of childhood nephrotic syndrome. Front Pediatr 7:178. https:\/\/doi.org\/10.3389\/fped.2019.00178","journal-title":"Front Pediatr"},{"key":"4357_CR47","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1093\/ndtplus\/sfp087","volume":"2","author":"N Printza","year":"2009","unstructured":"Printza N, Papachristou F, Tzimouli V et al (2009) Peripheral CD19+ B cells are increased in children with active steroid-sensitive nephrotic syndrome. NDT Plus 2:435\u2013436. https:\/\/doi.org\/10.1093\/ndtplus\/sfp087","journal-title":"NDT Plus"},{"key":"4357_CR48","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1038\/ki.2013.211","volume":"84","author":"P Ravani","year":"2013","unstructured":"Ravani P, Ponticelli A, Siciliano C et al (2013) Rituximab is a safe and effective long-term treatment for children with steroid and calcineurin inhibitor-dependent idiopathic nephrotic syndrome. Kidney Int 84:1025\u20131033. https:\/\/doi.org\/10.1038\/ki.2013.211","journal-title":"Kidney Int"},{"key":"4357_CR49","doi-asserted-by":"publisher","unstructured":"Ling C, Wang X, Chen Z et al (2019) Altered B-lymphocyte homeostasis in idiopathic nephrotic syndrome. Front Pediatr 7.\u00a0https:\/\/doi.org\/10.3389\/fped.2019.00377","DOI":"10.3389\/fped.2019.00377"},{"key":"4357_CR50","doi-asserted-by":"publisher","DOI":"10.1159\/000511319","author":"C Ling","year":"2020","unstructured":"Ling C, Chen Z, Fan J et al (2020) Decreased circulating transitional B-cell to memory B-cell ratio is a risk factor for relapse in children with steroid-sensitive nephrotic syndrome. Nephron. https:\/\/doi.org\/10.1159\/000511319","journal-title":"Nephron"},{"key":"4357_CR51","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s00467-018-4095-z","volume":"34","author":"M Colucci","year":"2019","unstructured":"Colucci M, Carsetti R, Cascioli S et al (2019) B cell phenotype in pediatric idiopathic nephrotic syndrome. Pediatr Nephrol 34:177\u2013181. https:\/\/doi.org\/10.1007\/s00467-018-4095-z","journal-title":"Pediatr Nephrol"},{"key":"4357_CR52","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1681\/ASN.2015050523","volume":"27","author":"M Colucci","year":"2016","unstructured":"Colucci M, Carsetti R, Cascioli S et al (2016) B cell reconstitution after rituximab treatment in idiopathic nephrotic syndrome. J Am Soc Nephrol 27:1811\u20131822. https:\/\/doi.org\/10.1681\/ASN.2015050523","journal-title":"J Am Soc Nephrol"},{"key":"4357_CR53","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/pr.2016.200","volume":"81","author":"C Dossier","year":"2017","unstructured":"Dossier C, Jamin A, Desch\u00eanes G (2017) Idiopathic nephrotic syndrome: the EBV hypothesis. Pediatr Res 81:233\u2013239","journal-title":"Pediatr Res"},{"key":"4357_CR54","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.jaut.2017.12.014","volume":"89","author":"A Jamin","year":"2018","unstructured":"Jamin A, Berthelot L, Couderc A et al (2018) Autoantibodies against podocytic UCHL1 are associated with idiopathic nephrotic syndrome relapses and induce proteinuria in mice. J Autoimmun 89:149\u2013161. https:\/\/doi.org\/10.1016\/j.jaut.2017.12.014","journal-title":"J Autoimmun"},{"issue":"28","key":"4357_CR55","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/S00467-012-2310-X","volume":"283","author":"RM Lombel","year":"2012","unstructured":"Lombel RM, Gipson DS (2012) Hodson EM (2012) Treatment of steroid-sensitive nephrotic syndrome: new guidelines from KDIGO. Pediatr Nephrol 283(28):415\u2013426. https:\/\/doi.org\/10.1007\/S00467-012-2310-X","journal-title":"Pediatr Nephrol"},{"key":"4357_CR56","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/J.KINT.2021.05.015","volume":"100","author":"BH Rovin","year":"2021","unstructured":"Rovin BH, Adler SG, Barratt J et al (2021) Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases. Kidney Int 100:753\u2013779. https:\/\/doi.org\/10.1016\/J.KINT.2021.05.015","journal-title":"Kidney Int"},{"key":"4357_CR57","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1007\/S00467-020-04519-1","volume":"35","author":"A Trautmann","year":"2020","unstructured":"Trautmann A, Vivarelli M, Samuel S et al (2020) IPNA clinical practice recommendations for the diagnosis and management of children with steroid-resistant nephrotic syndrome. Pediatr Nephrol 35:1529. https:\/\/doi.org\/10.1007\/S00467-020-04519-1","journal-title":"Pediatr Nephrol"},{"key":"4357_CR58","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1084\/JEM.20180595","volume":"216","author":"LM Franco","year":"2019","unstructured":"Franco LM, Gadkari M, Howe KN et al (2019) Immune regulation by glucocorticoids can be linked to cell type\u2013dependent transcriptional responses. J Exp Med 216:384. https:\/\/doi.org\/10.1084\/JEM.20180595","journal-title":"J Exp Med"},{"key":"4357_CR59","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/J.MCE.2010.04.005","volume":"335","author":"AE Coutinho","year":"2011","unstructured":"Coutinho AE, Chapman KE (2011) The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights. Mol Cell Endocrinol 335:2. https:\/\/doi.org\/10.1016\/J.MCE.2010.04.005","journal-title":"Mol Cell Endocrinol"},{"key":"4357_CR60","doi-asserted-by":"publisher","first-page":"2701","DOI":"10.1084\/JEM.20190738","volume":"216","author":"A Tokunaga","year":"2019","unstructured":"Tokunaga A, Sugiyama D, Maeda Y et al (2019) Selective inhibition of low-affinity memory CD8+ T cells by corticosteroids. J Exp Med 216:2701\u20132713. https:\/\/doi.org\/10.1084\/JEM.20190738","journal-title":"J Exp Med"},{"key":"4357_CR61","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1084\/JEM.193.7.803","volume":"193","author":"LF Van","year":"2001","unstructured":"Van LF, Baus E, Smyth LA et al (2001) Glucocorticoids attenuate T cell receptor signaling. J Exp Med 193:803. https:\/\/doi.org\/10.1084\/JEM.193.7.803","journal-title":"J Exp Med"},{"key":"4357_CR62","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/J.1365-2133.1990.TB02876.X","volume":"122","author":"JF Borel","year":"1990","unstructured":"Borel JF (1990) Mechanism of action and rationale for cyclosporin A in psoriasis. Br J Dermatol 122:5\u201312. https:\/\/doi.org\/10.1111\/J.1365-2133.1990.TB02876.X","journal-title":"Br J Dermatol"},{"key":"4357_CR63","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1038\/nm.1857","volume":"14","author":"C Faul","year":"2008","unstructured":"Faul C, Donnelly M, Merscher-Gomez S et al (2008) The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat Med 14:931\u2013938. https:\/\/doi.org\/10.1038\/nm.1857","journal-title":"Nat Med"},{"key":"4357_CR64","doi-asserted-by":"publisher","first-page":"31465","DOI":"10.1371\/JOURNAL.PONE.0031465","volume":"7","author":"K Tsuda","year":"2012","unstructured":"Tsuda K, Yamanaka K, Kitagawa H et al (2012) Calcineurin inhibitors suppress cytokine production from memory T cells and differentiation of na\u00efve T cells into cytokine-producing mature T cells. PLoS ONE 7:31465. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0031465","journal-title":"PLoS ONE"},{"key":"4357_CR65","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1111\/j.1365-2249.2009.04051.x","volume":"159","author":"S Heidt","year":"2010","unstructured":"Heidt S, Roelen DL, Eijsink C et al (2010) Calcineurin inhibitors affect B cell antibody responses indirectly by interfering with T cell help. Clin Exp Immunol 159:199\u2013207. https:\/\/doi.org\/10.1111\/j.1365-2249.2009.04051.x","journal-title":"Clin Exp Immunol"},{"key":"4357_CR66","doi-asserted-by":"publisher","unstructured":"Hilchey SP, Palshikar MG, Emo JA et al (2020) Cyclosporine a directly affects human and mouse b cell migration in vitro by disrupting a hIF-1 \u03b1dependent, o2 sensing, molecular switch. BMC Immunol 21.\u00a0https:\/\/doi.org\/10.1186\/s12865-020-0342-8","DOI":"10.1186\/s12865-020-0342-8"},{"key":"4357_CR67","doi-asserted-by":"publisher","unstructured":"Allison A (2016) Mechanisms of action of mycophenolate mofetil: 14:2\u20138. https:\/\/doi.org\/10.1191\/0961203305LU2109OA","DOI":"10.1191\/0961203305LU2109OA"},{"key":"4357_CR68","doi-asserted-by":"publisher","first-page":"860","DOI":"10.3390\/JCM8060860","volume":"8","author":"AK M\u00fchlig","year":"2019","unstructured":"M\u00fchlig AK, Lee JY, Kemper MJ et al (2019) Levamisole in children with idiopathic nephrotic syndrome: clinical efficacy and pathophysiological aspects. J Clin Med 8:860. https:\/\/doi.org\/10.3390\/JCM8060860","journal-title":"J Clin Med"},{"key":"4357_CR69","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/J.JNEUROIM.2003.10.036","volume":"146","author":"A Karni","year":"2004","unstructured":"Karni A, Balashov K, Hancock W et al (2004) Cyclophosphamide modulates CD4+ T cells into a T helper type 2 phenotype and reverses increased IFN-gamma production of CD8+ T cells in secondary progressive multiple sclerosis. J Neuroimmunol 146:189\u2013198. https:\/\/doi.org\/10.1016\/J.JNEUROIM.2003.10.036","journal-title":"J Neuroimmunol"},{"key":"4357_CR70","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1007\/S00262-006-0225-8","volume":"56","author":"F Ghiringhelli","year":"2007","unstructured":"Ghiringhelli F, Menard C, Puig P et al (2007) Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 56:641\u2013648. https:\/\/doi.org\/10.1007\/S00262-006-0225-8","journal-title":"Cancer Immunol Immunother"},{"key":"4357_CR71","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1056\/NEJMoa1304572","volume":"369","author":"C-C Yu","year":"2013","unstructured":"Yu C-C, Fornoni A, Weins A et al (2013) Abatacept in B7\u20131\u2013positive proteinuric kidney disease. N Engl J Med 369:2416\u20132423. https:\/\/doi.org\/10.1056\/NEJMoa1304572","journal-title":"N Engl J Med"},{"key":"4357_CR72","unstructured":"Pilot study to evaluate the safety and efficacy of abatacept in adults and children 6 years and older with excessive loss of protein in the urine due to either focal segmental glomerulosclerosis (FSGS) or minimal change disease (MCD) - Full Text View - ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02592798. Accessed 2 Oct 2021"},{"key":"4357_CR73","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.ekir.2017.08.013","volume":"3","author":"H Trachtman","year":"2018","unstructured":"Trachtman H, Gipson DS, Somers M et al (2018) Randomized clinical trial design to assess abatacept in resistant nephrotic syndrome. Kidney Int Reports 3:115\u2013121. https:\/\/doi.org\/10.1016\/j.ekir.2017.08.013","journal-title":"Kidney Int Reports"},{"key":"4357_CR74","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1016\/J.EKIR.2019.05.1155","volume":"4","author":"R Isom","year":"2019","unstructured":"Isom R, Shoor S, Higgins J et al (2019) Abatacept in steroid-dependent minimal change disease and CD80-uria. Kidney Int Reports 4:1349\u20131353. https:\/\/doi.org\/10.1016\/J.EKIR.2019.05.1155","journal-title":"Kidney Int Reports"},{"key":"4357_CR75","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1007\/s00467-019-04251-5","volume":"34","author":"H Sawires","year":"2019","unstructured":"Sawires H, Abdelaziz H, Ahmed HM et al (2019) Randomized controlled trial on immunomodulatory effects of azithromycin in children with steroid-dependent nephrotic syndrome. Pediatr Nephrol 34:1591\u20131597. https:\/\/doi.org\/10.1007\/s00467-019-04251-5","journal-title":"Pediatr Nephrol"},{"key":"4357_CR76","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/nrneph.2012.115","volume":"8","author":"LA Greenbaum","year":"2012","unstructured":"Greenbaum LA, Benndorf R, Smoyer WE (2012) Childhood nephrotic syndrome\u2014current and future therapies. Nat Rev Nephrol 8:445\u2013458. https:\/\/doi.org\/10.1038\/nrneph.2012.115","journal-title":"Nat Rev Nephrol"},{"key":"4357_CR77","doi-asserted-by":"publisher","unstructured":"Oshima Y, Sumida K, Yamanouchi M et al (2020) Corticosteroid reduction by addition of cetirizine and montelukast in biopsy-proven minimal-change nephrotic syndrome concomitant with allergic disorders. Sci Rep 10.\u00a0https:\/\/doi.org\/10.1038\/s41598-020-58463-z","DOI":"10.1038\/s41598-020-58463-z"},{"key":"4357_CR78","doi-asserted-by":"publisher","unstructured":"Basu B (2014) Ofatumumab for rituximab-resistant nephrotic syndrome. 370:1268\u20131270. https:\/\/doi.org\/10.1056\/NEJMC1308488","DOI":"10.1056\/NEJMC1308488"},{"key":"4357_CR79","doi-asserted-by":"publisher","DOI":"10.1111\/PETR.13175","volume":"22","author":"J Bernard","year":"2018","unstructured":"Bernard J, Bruel A, Allain-Launay E et al (2018) Ofatumumab in post-transplantation recurrence of a pediatric steroid-resistant idiopathic nephrotic syndrome. Pediatr Transplant 22:e13175. https:\/\/doi.org\/10.1111\/PETR.13175","journal-title":"Pediatr Transplant"},{"issue":"35","key":"4357_CR80","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1007\/S00467-020-04567-7","volume":"358","author":"J Bernard","year":"2020","unstructured":"Bernard J, Lalieve F, Sarlat J et al (2020) Ofatumumab treatment for nephrotic syndrome recurrence after pediatric renal transplantation. Pediatr Nephrol 358(35):1499\u20131506. https:\/\/doi.org\/10.1007\/S00467-020-04567-7","journal-title":"Pediatr Nephrol"},{"key":"4357_CR81","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1007\/s00467-017-3621-8","volume":"32","author":"C-S Wang","year":"2017","unstructured":"Wang C-S, Liverman RS, Garro R et al (2017) Ofatumumab for the treatment of childhood nephrotic syndrome. Pediatr Nephrol 32:835\u2013841. https:\/\/doi.org\/10.1007\/s00467-017-3621-8","journal-title":"Pediatr Nephrol"},{"key":"4357_CR82","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/S00467-020-04811-0","volume":"36","author":"C Dossier","year":"2021","unstructured":"Dossier C, Prim B, Moreau C et al (2021) A global antiB cell strategy combining obinutuzumab and daratumumab in severe pediatric nephrotic syndrome. Pediatr Nephrol 36:1. https:\/\/doi.org\/10.1007\/S00467-020-04811-0","journal-title":"Pediatr Nephrol"}],"container-title":["European Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-021-04357-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00431-021-04357-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-021-04357-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T09:18:38Z","timestamp":1648545518000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00431-021-04357-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,31]]},"references-count":82,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["4357"],"URL":"https:\/\/doi.org\/10.1007\/s00431-021-04357-9","relation":{},"ISSN":["1432-1076"],"issn-type":[{"value":"1432-1076","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,31]]},"assertion":[{"value":"16 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}